|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Tong-Hsuan Chang | Mei-Chun Yang | Roger Lu | (02)2697-4168 | 8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist.,New Taipei City 22175,Taiwan | 2012/12/18 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Marching into 2015, GlycoNex has possessed advanced and complete technology platform: 1.glycosphingolipid antigen production and identification 2.monoclonal antibody production 3.cancer drug screening 4.stable cell line production for monoclonal antibody 5.process development and downstream purification The development of monoclonal antibody cancer drug has made tremendous progress. The mAbs of GlycoNex's research have been successfully licensed to a renowned international pharmaceutical co. in 2009, and IND application is scheduled to be filed in 2015. GlycoNex also utilizes its expertise on monoclonal antibody to march into CRO business. The CRO-CMO strategic alliance has been formed in 2010 between GlycoNex and Mitsubishi Gas Chemical Company Inc (MGC). |
Market Information ( 2024/04/19 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
329.09 | 26.15 | 25.00 | 25.40 | -0.65 | 260 | .00 | 3,672 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/19) |
TPEx measures adopted (2024/04/19) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |